The post Why This Bitcoin Price Rally May Not Last appeared first on Coinpedia Fintech News Bitcoin finally looks alive again. After months of going nowhere, theThe post Why This Bitcoin Price Rally May Not Last appeared first on Coinpedia Fintech News Bitcoin finally looks alive again. After months of going nowhere, the

Why This Bitcoin Price Rally May Not Last

2026/01/16 23:29
3 min read
Bitcoin Price Prediction

The post Why This Bitcoin Price Rally May Not Last appeared first on Coinpedia Fintech News

Bitcoin finally looks alive again.

After months of going nowhere, the price pushed up toward $98,000 and is now holding above $96,000. For the first time in a while, crypto traders are feeling some real momentum. But beneath the surface, not everyone is convinced this move will last.

According to Michael Nadeau, the market’s structure tells a more bearish story, one that could mean this rally could fade if conditions are not met.

The hidden force holding Bitcoin back

One of the biggest factors shaping Bitcoin right now is not hype, ETFs, or social media buzz. It is real interest rates.

Nadeau points out that Bitcoin often struggles when real interest rates rise. This happened clearly in 2022, when aggressive rate hikes crushed crypto prices. What stands out today is that since mid-October, real rates have started climbing again, and Bitcoin’s relationship with them has turned negative.

In simple terms, when safer investments start paying more, money tends to move away from risky assets like crypto. That shift can quietly limit how far Bitcoin can run.

Why cycles still matter in crypto

Many traders love talking about the famous four-year Bitcoin cycle. Nadeau believes in cycles too, but not in a rigid, copy-paste way.

“I’m a firm believer in cycles,” he said, but added that markets evolve.

Instead of focusing on a calendar, he looks at how money flows through the system. In his view, crypto cycles usually move through three stages:

  • An early bull phase
  • A period of wealth creation
  • A phase where that wealth gets distributed

When he looks at this cycle, Nadeau sees signs that all three stages may already be behind us.

Signs the easy money phase is over

Earlier in the cycle, crypto saw explosive growth. DeFi lending boomed. New crypto companies raised huge sums. IPOs and digital asset treasury plays took off. Marketing budgets were everywhere.

Now, much of that energy has cooled.

To Nadeau, this looks less like the start of something new and more like a market that has already had its big run and is now sorting out who stays and who exits.

The one level Bitcoin must reclaim

From a chart perspective, Nadeau is watching one level very closely: the 50-week moving average. Bitcoin lost this level in October and then fell around 35%. Since then, on-chain data shows heavy coin movement, a classic sign of late-cycle rotation.

He expected a bounce back toward this zone, roughly between $101,000 and $102,000, and the recent move into the high $90,000s fits that script.

But here is the catch.

Unless Bitcoin can move above that level and stay there for several weeks, the rally does not become real support. “I’m not convinced this is a durable move,” Nadeau said, stressing that short-term strength alone is not enough.

ETFs are helping, but they are not the whole story

There are some positives. Bitcoin ETFs are seeing fresh inflows, and long-term holders appear less eager to send coins to exchanges, which reduces selling pressure.

Still, Nadeau views these as supportive, not decisive. Without a clear technical breakout, ETF demand alone may not be enough to push Bitcoin into a new long-term uptrend.

Over the next few weeks, Bitcoin will need to prove it can turn resistance into support. If it cannot, this burst of strength could end up being just another pause, not the start of the next major run.

Market Opportunity
Notcoin Logo
Notcoin Price(NOT)
$0.0003846
$0.0003846$0.0003846
-1.02%
USD
Notcoin (NOT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03